Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease

Nature Clinical Practice Gastroenterology & Hepatology volume 2, pages 210–211 (2005)Cite this article

boxed-textSchoon EJ et al. (2005) Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 3: 113–121

CR Budesonide should be considered as the first-line therapy for mild to moderate ileal or ileocecal Crohn's disease in corticosteroid-naive patients

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Siffiledeen JS et al. (2004) Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis 10: 220–228

    Article  Google Scholar 

  2. Bernstein CN et al. (2000) The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 133: 795–799

    Article  CAS  Google Scholar 

  3. Loftus EV Jr et al. (2002) Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 123: 468–475

    Article  Google Scholar 

  4. Stockbrugger RW et al. (2002) Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 16: 1519–1527

    Article  CAS  Google Scholar 

  5. Kane SV et al. (2002) The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 16: 1509–1517

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor and Director of the Center for Inflammatory Bowel Disease at the Mount Sinai School of Medicine, New York, NY, USA

    Maria T Abreu

Authors
  1. Maria T Abreu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria T Abreu.

Ethics declarations

Competing interests

MT Abreu has received research grants from Procter and Gamble and Centocor. She is also a member of the Speaker's bureau for Procter and Gamble, Centocor, Prometheus, Abbott Laboratories and Salix Pharmaceuticals.

Glossary

OSTEOPOROSIS

Decrease in bone mineral density of 2.5 standard deviations compared with peak bone density (T-score), or with an age-matched population (Z-score)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abreu, M. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease. Nat Rev Gastroenterol Hepatol 2, 210–211 (2005). https://doi.org/10.1038/ncpgasthep0173

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0173

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing